About

About Nuvisan About NUVISAN The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. Your partner of choice in bringing therapeutics to life. Nuvisan is a full-service CRO and CDMO with state-of-the-art facilities in Germany and France, supporting pharmaceutical, biotech, venture capital and non-profit partners with high-quality, end-to-end solutions that accelerate the journey from early discovery to clinical development. With more than 40 years of heritage, Nuvisan has built a reputation for scientific excellence, industry expertise and seamless integration across discovery, development and manufacturing. Our centres of excellence, including drug discovery in Berlin, provide comprehensive capabilities to advance complex programs efficiently. In oncology, Nuvisan offers a comprehensive portfolio of specialised technologies and models designed to accelerate cancer therapeutic innovation. Our capabilities encompass target validation, CRISPR/RNAi screening, custom assay development, next-generation sequencing, single-cell analyses, multiplex flow cytometry, biomarker discovery and in vivo pharmacology including PK/PD and efficacy studies. With an extensive collection of cancer models and deep translational expertise, we support programs across solid tumours, hematologic malignancies, immuno-oncology and novel therapeutic modalities. By working collaboratively to adapt to each client’s unique needs, we help de-risk development and expedite the delivery of impactful oncology therapeutics to patients worldwide. The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. Your partner of choice in bringing therapeutics to life Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France. Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life. Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project. Discovery: Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration. Preclinical: Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic. CMC: Collaborating with you to advance molecules into drug products. Clinical: Providing tailored clinical solutions to fully assess your drug faster. Digital: Empowering your drug discovery and development with integrated data services, machine learning and generative AI. Research phases Supporting you with integrated, tailored solutions at every step of your drug discovery and development journey.